Tonix Pharma expands share repurchase program by $25M to $35M total authorized

Tonix Pharmaceuticals Holding Corp.

Board approved an additional $25.0 million for share repurchases, raising total authorized to $35.0 million.
Repurchases may occur from time to time in open-market or private transactions depending on conditions.
The original $10 million authorization was increased; no expiration date or commitment to repurchase any specific number of shares.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.